1,648
Views
0
CrossRef citations to date
0
Altmetric
Cardiology & Cardiovascular Disorders

The prediction value of platelet-derived growth factor for major adverse cardiovascular events in patients with acute non-ST-segment elevation myocardial infarction

, , , , , , & show all
Pages 1047-1057 | Received 23 Nov 2022, Accepted 30 Jan 2023, Published online: 13 Mar 2023

References

  • Liu M, Zhang L, Tao S, et al. Anti-Inflammation relieving heart dysfunction and depressive behaviors of mice under myocardial infarction and chronic stress. Heart and Mind. 2022;6(3):159–166.
  • Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA. 2022;327(7):662–675.
  • Valina C, Neumann FJ, Menichelli M, et al. Ticagrelor or prasugrel in patients with Non-ST-Segment elevation acute coronary syndromes. J Am Coll Cardiol. 2020;76(21):2436–2446.
  • Geng Y, Wang Y, Liu L, et al. Staged revascularization for chronic total occlusion in the non-IRA in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: an updated systematic review and meta-analysis. Cardiovasc Innovat Appl. 2022;6(4):209–218.
  • Pang S, Tao Z, Min X, et al. Correlation between the serum platelet-derived growth factor, angiopoietin-1, and severity of coronary heart disease. Cardiol Res Pract. 2020;2020:3602608.
  • Koizumi T, Komiyama N, Nishimura S. In-vivo higher plasma levels of platelet-derived growth factor and matrix metalloproteinase-9 in coronary artery at the very onset of myocardial infarction with ST-segment elevation. Ann Vasc Dis. 2015;8(4):297–301.
  • Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target. Mol Aspects Med. 2018;62:75–88.
  • Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367.
  • Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139–e228.
  • McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726.
  • Zhuang W, Chen J, Li Y, et al. Valuation of lymph node dissection in localized high-risk renal cell cancer using X-tile software. Int Urol Nephrol. 2020;52(2):253–262.
  • Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259.
  • Medamana J, Clark RA, Butler J. Platelet-derived growth factor in heart failure. Handb Exp Pharmacol. 2017;243:355–369.
  • Kalra K, Eberhard J, Farbehi N, et al. Role of PDGF-A/B ligands in cardiac repair after myocardial infarction. Front Cell Dev Biol. 2021;9:669188.
  • Kurtul A, Ornek E. Platelet to lymphocyte ratio in cardiovascular diseases: a systematic review. Angiology. 2019;70(9):802–818.
  • Heldin CH, Lennartsson J, Westermark B. Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis. J Intern Med. 2018;283(1):16–44.
  • Santhanam L, Liu G, Jandu S, et al. Skeleton-secreted PDGF-BB mediates arterial stiffening. J Clin Invest. 2021;131(20):1–20.
  • Koizumi T, Kaneda H, Yamasaki T, et al. Impact of platelet-derived growth factor-BB on ischemic myocardial injury after thrombus aspiration for ST-segment elevation myocardial infarction. Int J Cardiol. 2015;182:109–111.
  • Alehagen U, Olsen RS, Lanne T, et al. PDGF-D gene polymorphism is associated with increased cardiovascular mortality in elderly men. BMC Med Genet. 2016;17(1):62.
  • Yang X, Zhan P, Wang X, et al. Polydopamine-assisted PDGF-BB immobilization on PLGA fibrous substrate enhances wound healing via regulating anti-inflammatory and cytokine secretion. PLoS One. 2020;15(9):e0239366.
  • Hsieh PC, Davis ME, Gannon J, et al. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest. 2006;116(1):237–248.
  • Hsieh PC, MacGillivray C, Gannon J, et al. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation. 2006;114(7):637–644.
  • Folestad E, Kunath A, Wågsäter D. PDGF-C and PDGF-D signaling in vascular diseases and animal models. Mol Aspects Med. 2018;62:1–11.
  • Guerit E, Arts F, Dachy G, et al. PDGF receptor mutations in human diseases. Cell Mol Life Sci. 2021;78(8):3867–3881.
  • Cui K, Zhou X, Luo J, et al. Dual gene transfer of bFGF and PDGF in a single plasmid for the treatment of myocardial infarction. Exp Ther Med. 2014;7(3):691–696.
  • Frangogiannis NG. Platelet-derived growth factor (PDGF) therapy in myocardial infarction: challenges and opportunities. Int J Cardiol. 2021;341:74–75.
  • Rashid FN, Clayton ZE, Ogawa M, et al. Platelet derived growth factor-A (pdgf-a) gene transfer modulates scar composition and improves left ventricular function after myocardial infarction. Int J Cardiol. 2021;341:24–30.
  • Zhang Y, Lin P, Jiang H, et al. Extensive serum biomarker analysis in patients with ST segment elevation myocardial infarction (STEMI). Cytokine. 2015;76(2):356–362.
  • Hung J, Roos A, Kadesjo E, et al. Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction. Eur Heart J. 2021;42(26):2552–2561.
  • Emami AS, Bairey Merz CN, Eastwood JA, et al. Somatic versus cognitive depressive symptoms as predictors of coronary artery disease among women with suspected ischemia: the women’s ischemia syndrome evaluation. Heart Mind. 2021;5(4):112–118.